Literature DB >> 21690317

CHRNA3 rs1051730 genotype and short-term smoking cessation.

Marcus R Munafò1, Elaine C Johnstone, Donna Walther, George R Uhl, Michael F G Murphy, Paul Aveyard.   

Abstract

INTRODUCTION: The rs1051730 genetic variant within the CHRNA5-A3-B4 gene cluster is associated with heaviness of smoking and has recently been reported to be associated with likelihood of stopping smoking. We investigated the potential association of rs1051730 genotype with reduced likelihood of smoking cessation in 2 cohorts of treatment-seeking smokers in primary care in the United Kingdom.
METHODS: Data were drawn from 2 clinical trials on which DNA was available. One sample was a randomized placebo-controlled trial of nicotine transdermal patch and the other sample an open-label trial where all participants received nicotine transdermal patch. Smoking status was biochemically verified. Logistic regression was used to assess evidence for association in each sample, and data were combined within a meta-analysis.
RESULTS: There was evidence of association of rs1051730 genotype with short-term (4-week) cessation in our open-label trial sample but not our placebo-controlled trial sample. When combined in a meta-analysis, this effect remained. There was no evidence of association at later follow-up intervals. Adjustment for cigarette consumption and tobacco dependence did not alter these results substantially.
CONCLUSIONS: Our data, taken together with previous recent studies, provide some support for a weak association between this variant and short-term smoking cessation in treatment-seeking smokers, which does not seem to operate only among those receiving nicotine replacement therapy. Moreover, the rs1051730 variant may not merely operate as a marker for dependence or heaviness of smoking.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21690317      PMCID: PMC3179672          DOI: 10.1093/ntr/ntr106

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  36 in total

1.  Outcome criteria in smoking cessation trials: proposal for a common standard.

Authors:  Robert West; Peter Hajek; Lindsay Stead; John Stapleton
Journal:  Addiction       Date:  2005-03       Impact factor: 6.526

2.  Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.

Authors:  Caryn Lerman; Christopher Jepson; E Paul Wileyto; Leonard H Epstein; Margaret Rukstalis; Freda Patterson; Vyga Kaufmann; Stephanie Restine; Larry Hawk; Ray Niaura; Wade Berrettini
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

Review 3.  Pharmacogenetics and nicotine addiction treatment.

Authors:  Marcus R Munafò; Alexandra E Shields; Wade H Berrettini; Freda Patterson; Caryn Lerman
Journal:  Pharmacogenomics       Date:  2005-04       Impact factor: 2.533

4.  Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence.

Authors:  J P Dahl; C Jepson; R Levenson; E P Wileyto; F Patterson; W H Berrettini; C Lerman
Journal:  Pharmacogenomics J       Date:  2006 May-Jun       Impact factor: 3.550

5.  Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.

Authors:  V Malaiyandi; C Lerman; N L Benowitz; C Jepson; F Patterson; R F Tyndale
Journal:  Mol Psychiatry       Date:  2006-04       Impact factor: 15.992

6.  Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial.

Authors:  Marcus R Munafò; Elaine C Johnstone; E Paul Wileyto; Peter G Shields; Katherine M Elliot; Caryn Lerman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-02       Impact factor: 4.254

7.  Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.

Authors:  F E Pontieri; G Tanda; F Orzi; G Di Chiara
Journal:  Nature       Date:  1996-07-18       Impact factor: 49.962

Review 8.  The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected].

Authors:  David J K Balfour
Journal:  Nicotine Tob Res       Date:  2004-12       Impact factor: 4.244

9.  Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.

Authors:  Caryn Lerman; Rachel Tyndale; Freda Patterson; E Paul Wileyto; Peter G Shields; Angela Pinto; Neal Benowitz
Journal:  Clin Pharmacol Ther       Date:  2006-05-11       Impact factor: 6.875

10.  Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs.

Authors:  Scott F Saccone; Anthony L Hinrichs; Nancy L Saccone; Gary A Chase; Karel Konvicka; Pamela A F Madden; Naomi Breslau; Eric O Johnson; Dorothy Hatsukami; Ovide Pomerleau; Gary E Swan; Alison M Goate; Joni Rutter; Sarah Bertelsen; Louis Fox; Douglas Fugman; Nicholas G Martin; Grant W Montgomery; Jen C Wang; Dennis G Ballinger; John P Rice; Laura Jean Bierut
Journal:  Hum Mol Genet       Date:  2006-11-29       Impact factor: 6.150

View more
  50 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 2.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

3.  Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.

Authors:  Li-Shiun Chen; Timothy B Baker; Megan E Piper; Naomi Breslau; Dale S Cannon; Kimberly F Doheny; Stephanie M Gogarten; Eric O Johnson; Nancy L Saccone; Jen C Wang; Robert B Weiss; Alison M Goate; Laura Jean Bierut
Journal:  Am J Psychiatry       Date:  2012-07       Impact factor: 18.112

4.  The genetic basis of addictive disorders.

Authors:  Francesca Ducci; David Goldman
Journal:  Psychiatr Clin North Am       Date:  2012-06

5.  The value of control conditions for evaluating pharmacogenetic effects.

Authors:  Li-Shiun Chen; Timothy B Baker; Laura J Bierut
Journal:  Pharmacogenomics       Date:  2015-11-26       Impact factor: 2.533

Review 6.  CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis.

Authors:  Li-Shiun Chen; Rayjean J Hung; Timothy Baker; Amy Horton; Rob Culverhouse; Nancy Saccone; Iona Cheng; Bo Deng; Younghun Han; Helen M Hansen; Janet Horsman; Claire Kim; Sharon Lutz; Albert Rosenberger; Katja K Aben; Angeline S Andrew; Naomi Breslau; Shen-Chih Chang; Aida Karina Dieffenbach; Hendrik Dienemann; Brittni Frederiksen; Jiali Han; Dorothy K Hatsukami; Eric O Johnson; Mala Pande; Margaret R Wrensch; John McLaughlin; Vidar Skaug; Henricus F van der Heijden; Jason Wampfler; Angela Wenzlaff; Penella Woll; Shanbeh Zienolddiny; Heike Bickeböller; Hermann Brenner; Eric J Duell; Aage Haugen; Joachim Heinrich; John E Hokanson; David J Hunter; Lambertus A Kiemeney; Philip Lazarus; Loic Le Marchand; Geoffrey Liu; Jose Mayordomo; Angela Risch; Ann G Schwartz; Dawn Teare; Xifeng Wu; John K Wiencke; Ping Yang; Zuo-Feng Zhang; Margaret R Spitz; Peter Kraft; Christopher I Amos; Laura J Bierut
Journal:  J Natl Cancer Inst       Date:  2015-04-14       Impact factor: 13.506

7.  From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.

Authors:  Naji C Salloum; Erica L F Buchalter; Swati Chanani; Gemma Espejo; Mahjabeen S Ismail; Randy O Laine; Maysaa Nageeb; A Benjamin Srivastava; Nicholas Trapp; Ludwig Trillo; Erica Vance; Michael Wenzinger; Sarah M Hartz; Sean P David; Li-Shiun Chen
Journal:  Pharmacogenomics       Date:  2018-06-19       Impact factor: 2.533

Review 8.  Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?

Authors:  Henry R Kranzler; Rachel V Smith; Robert Schnoll; Afaf Moustafa; Emma Greenstreet-Akman
Journal:  Addiction       Date:  2017-04-21       Impact factor: 6.526

Review 9.  Biomarkers for smoking cessation.

Authors:  K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur
Journal:  Clin Pharmacol Ther       Date:  2013-03-18       Impact factor: 6.875

10.  Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.

Authors:  Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Denise Nishita; Martha Michel; David V Conti; Jinghua Liu; Won Lee; Christopher K Edlund; Sharon Hall; Pui-Yan Kwok; Neal L Benowitz; Timothy B Baker; Rachel F Tyndale; Caryn Lerman; Gary E Swan
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.